What Is Retatrutide?
Retatrutide (also known as LY-3437943, with CAS number 2381089-83-2) is a novel triple hormone receptor agonist developed by Eli Lilly and Company, a leading American pharmaceutical enterprise. It is a 39-amino-acid peptide drug that simultaneously targets and activates three key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), making it a breakthrough in the treatment of metabolic disorders such as obesity and type 2 diabetes.
How It Works?
GLP-1 is a naturally occurring gut hormone released after eating. Retatrutide mimics its action by binding to GLP-1R, triggering three core effects:
- Appetite suppression: Signals the brain’s hypothalamus to reduce hunger and increase satiety, leading to reduced food intake (e.g., smaller meal portions, fewer cravings for high-calorie foods).
- Delayed gastric emptying: Slows the rate at which food moves from the stomach to the intestines, prolonging feelings of fullness and preventing rapid spikes in blood sugar.
- Glucose-dependent insulin secretion: Stimulates the pancreas to release insulin only when blood sugar is high (avoids hypoglycemia risk), while inhibiting glucagon (a hormone that raises blood sugar), stabilizing glucose levels.
GIP (another gut hormone) works in tandem with GLP-1 but has unique synergistic benefits when activated alongside it:
- Enhanced insulin sensitivity: Improves how cells respond to insulin, helping muscles, fat, and liver tissues efficiently absorb glucose—critical for reversing insulin resistance (a key driver of type 2 diabetes and obesity).
- Lipid metabolism regulation: Reduces the storage of fat in the liver and visceral organs (abdominal fat), lowering the risk of non-alcoholic fatty liver disease (NAFLD) and cardiovascular complications.
- Amplified weight loss: GIPR activation boosts the "fat-burning" effects of GLP-1R, accelerating the breakdown of stored fat for energy. Clinical data shows this synergy increases weight loss by 20-30% compared to GLP-1-only drugs.
Glucagon (a hormone produced by the pancreas) is often seen as the "counterpart" to insulin, but when activated moderately (as Retatrutide does), it delivers metabolic benefits:
- Increased energy expenditure: Stimulates the liver to break down glycogen (stored glucose) into usable energy, while promoting thermogenesis (heat production) in fat tissue—burning more calories even at rest.
- Reduced liver fat: Inhibits de novo lipogenesis (the production of new fat in the liver), a major contributor to NAFLD. Clinical trials show Retatrutide reduces liver fat by up to 86% in 24 weeks.
- Glucose regulation: While glucagon can raise blood sugar at high doses, Retatrutide’s balanced activation (paired with GLP-1R/GIPR) mitigates this risk—instead, it helps normalize glucose levels by balancing insulin and glucagon activity.
Key Features & Benefits
- Triple-receptor synergy: Activates GLP-1R/GIPR/GCGR simultaneously, outperforming single/dual-target therapies.
- Superior weight loss: 22.8-24.2% average reduction (Phase 2), targeting both subcutaneous and visceral fat.
- Robust glycemic control: Lowers HbA1c by 2.5-3.0%, improves insulin resistance and pancreatic function.
- NAFLD breakthrough: Reduces liver fat by up to 86% in 24 weeks, eases liver inflammation.
- Balanced safety profile: Mild, transient GI side effects; weekly subcutaneous injection for convenience.
- Comprehensive metabolic support: Boosts lean muscle, energy expenditure, and lipid regulation.
Applications
- Obesity & Overweight Management
- Type 2 Diabetes Mellitus (T2DM)
- Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
- Metabolic Syndrome
Why Choose Us?
- High-purity peptide synthesis
- Full quality documentation (COA, HPLC, MS)
- OEM/ODM private label support
- Reliable global delivery
- Stable bulk supply for distributors
